tbuckley/cabot-search huggingface dataset:
Quick Uptakes
Authors: Feyza Sancar
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML
Authors: Yehuda E. Deutsch, Justin T Presutto, Amanda Brahim, Jyotishankar Raychaudhuri, Marco Andres Ruiz, Jose Sandoval-Sus, Hugo F. Fernandez
Journal: Blood (2018)
High Mobility Group A1 Chromatin Remodeling Proteins Amplify Inflammatory Networks to Drive Leukemic Transformation in Chronic Myeloproliferative Neoplasia in Humans and JAK2V617F Transgenic Mouse Models
Authors: Linda Resar, Donna Marie Williams, Lingling Xian, Wenyan Lu, Briyana Chisholm, Li Luo, Zhizhuang Joe Zhao, Ophelia Rogers, Jerry L. Spivak, Alison R. Moliterno
Journal: Blood (2018)
Association Between Emergency Medical Service Response Time and Motor Vehicle Crash Mortality in the United States
Authors: James P. Byrne, N. Clay Mann, Mengtao Dai, Stephanie A. Mason, Paul Karanicolas, Sandro Rizoli, Avery B. Nathens
Journal: JAMA Surgery (2019)

<h3>Importance</h3> Motor vehicle crashes (MVCs) are a leading public health concern. Emergency medical service (EMS) response time is a modifiable, system-level factor with the potential to influence trauma patient survival. The relationship between EMS response time and MVC mortality is unknown. <h3>Objectives</h3> To measure the association between EMS response times and MVC mortality at the population level across US counties. <h3>Design, Setting, and Study Population</h3> This population-based study included MVC-related deaths in 2268 US counties, representing an estimated population of 239 464 121 people, from January 1, 2013, through December 31, 2015. Data were analyzed from October 1, 2017, through April 30, 2018. <h3>Exposure</h3> The median EMS response time to MVCs within each county (county response time), derived from data collected by the National Emergency Medical Service Information System. <h3>Main Outcomes and Measures</h3> The county rate of MVC-related death, calculated using crash fatality data recorded in the Fatality Analysis Reporting System of the National Highway Traffic Safety Administration. <h3>Results</h3> During the study period, 2 214 480 ambulance responses to MVCs were identified (median, 229 responses per county [interquartile range (IQR), 73-697 responses per county]) in 2268 US counties. The median county response time was 9 minutes (IQR, 7-11) minutes. Longer response times were significantly associated with higher rates of MVC mortality (≥12 vs &lt;7 minutes; mortality rate ratio, 1.46; 95% CI, 1.32-1.61) after adjusting for measures of rurality, on-scene and transport times, access to trauma resources, and traffic safety laws. This finding was consistent in both rural/wilderness and urban/suburban settings, where a significant proportion of MVC fatalities (population attributable fraction: rural/wilderness, 9.9%; urban/suburban, 14.1%) were associated with prolonged response times (defined by the median value, ≥10 minutes and ≥7 minutes, respectively). <h3>Conclusions and Relevance</h3> Among 2268 US counties, longer EMS response times were associated with higher rates of MVC mortality. A significant proportion of MVC-related deaths were associated with prolonged response times in both rural/wilderness and urban/suburban settings. These findings suggest that trauma system–level efforts to address regional disparities in MVC mortality should evaluate EMS response times as a potential contributor.
Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments
Authors: Riccardo V. D'Elia, Stuart Woods, Wendy Butcher, Jonathan McGahon, Swapnil Khadke, Yvonne Perrie, E. Diane Williamson, Craig W. Roberts
Journal: Journal of Controlled Release (2019)

Burkholderia pseudomallei is a Gram-negative intracellular bacterium which is recalcitrant to antibiotic therapy. There also is currently no licensed vaccine for this potentially fatal pathogen, further highlighting the requirement for better therapeutics to treat the disease melioidosis. Here we use an oral delivery platform, the bilosome to entrap already- licensed antibiotics. Bilosome-entrapped antibiotics were used to treat mice infected via the aerosol route with B. pseudomallei. When treatment was started by the oral route at 6 h post-infection and continued for 7 days, bilosome levofloxacin and bilosome doxycycline formulations were significantly more efficacious than free antibiotics in terms of survival rates. Additionally, bilosome formulated levofloxacin protected mice from antibiotic and infection induced weight loss following B. pseudomallei infection. The microbiomes of mice treated with levofloxacin were depleted of all phyla with the exception of Firmicutes, but doxycycline treatment had minimal effect on the microbiome. Encapsulation of either drug in bilosomes had no deleterious or clear advantageous effect on microbiome. This indicates that the ability of bilosomes to ameliorate antibiotic induced weight loss is not due to microbiome effects. The bilosome platform not only has potential to reduce adverse effects of orally delivered antimicrobials, but has potential for other therapeutics which may cause detrimental side-effects or require enhanced delivery.
rAAV-based brain slice culture models of Alzheimer’s and Parkinson’s disease inclusion pathologies
Authors: Cara L. Croft, Pedro E. Cruz, Daniel H. Ryu, Carolina Ceballos-Diaz, Kevin H. Strang, Brittany M. Woody, Wen-Lang Lin, Michael Deture, Edgardo Rodríguez-Lebrón, Dennis W. Dickson, Paramita Chakrabarty, Yona Levites, Benoit I. Giasson, Todd E. Golde
Journal: The Journal of Experimental Medicine (2019)

It has been challenging to produce ex vivo models of the inclusion pathologies that are hallmark pathologies of many neurodegenerative diseases. Using three-dimensional mouse brain slice cultures (BSCs), we have developed a paradigm that rapidly and robustly recapitulates mature neurofibrillary inclusion and Lewy body formation found in Alzheimer’s and Parkinson’s disease, respectively. This was achieved by transducing the BSCs with recombinant adeno-associated viruses (rAAVs) that express α-synuclein or variants of tau. Notably, the tauopathy BSC model enables screening of small molecule therapeutics and tracking of neurodegeneration. More generally, the rAAV BSC “toolkit” enables efficient transduction and transgene expression from neurons, microglia, astrocytes, and oligodendrocytes, alone or in combination, with transgene expression lasting for many months. These rAAV-based BSC models provide a cost-effective and facile alternative to in vivo studies, and in the future can become a widely adopted methodology to explore physiological and pathological mechanisms related to brain function and dysfunction.
Abstract 433: The Role Of Claudin-5 on Mitochondrial Dynamics in Neonatal Rat Cardiomyocyte
Authors: Tao Luo, Han Liu, Jin K Kim
Journal: Circulation Research (2017)

Background: Claudin-5, an integral transmembrane protein that controls the para-cellular permeability, is severely downregulated in end stage cardiomyopathy and during ischemia-reperfusion injury. Sustaining claudin-5 levels prevented myocardial damage and dysfunction. However, the underlying mechanism behind the cardioprotection associated with claudin-5 is unclear. The aim of this study is therefore to investigate the role of claudin-5 on mitochondria in vitro . Methods and Results: Western blot showed that claudin-5 was expressed in mouse heart tissue and neonatal rat cardiomyocyte (NRCM). Its protein level was severely decreased after myocardial ischemia/reperfusion (I/R; 30 min/24 hr) and after hypoxia/reoxygenation (H/R; 24 hr/4 hr), respectively. Further in-vitro confocal observation showed that claudin-5 was co-expressed on mitochondria in NRCM and its decrease was accompanied by mitochondrial fragmentation. We then detected the mitochondrial fusion and fission proteins in NRCM under the condition of H/R. Claudin-5 siRNA and claudin-5 overexpressing adenovirus were used to knockdown claudin-5 and overexpress claudin-5. The protein level of mitofusin 2 (responsible for mitochondrial outer membrane fusion) was dramatically decreased while the expression of Drp 1 (responsible for mitochondrial fission) was significantly increased after H/R; Claudin-5 siRNA pretreatment further decreased the level of mitofusin 2 and increased the level of Drp 1. However, overexpression of claudin-5 reversed these effects respectively. We further measured the apoptotic protein, cytochrome c, by western blot. The expression of cytochrome c in the cytoplasm of NRCM was significantly increased after H/R, which was reduced by overexpression of claudin-5 by adenovirus. Conclusion: In the present study, we first time introduce a new concept that claudin-5 may help maintaining mitochondrial dynamics by upregulating mitochondrial fusion and suppressing mitochondrial fission.
Small cell lung cancers made from scratch
Authors: Adi F. Gazdar, John D. Minna
Journal: The Journal of Experimental Medicine (2019)

In this issue of JEM, Chen et al. (https://doi.org/10.1084/jem.20181155) describe a new approach for the transformation of human pluripotent embryonic stem cells (hESCs) into neuroendocrine (NE) tumors of the lung closely resembling human small cell lung cancer (SCLC). Another recent study uses a different method to transform fully differentiated normal human cells into high-grade NE tumors (Park et al. 2018. Science. https://doi.org/10.1126/science.aat5749). These approaches and their models provide important new resources for developing diagnostic, preventative, and therapeutic approaches for high-grade NE tumors.
Time for Advance Care Planning Discussions During Transitions in Care in Cancer Clinical Trials
Authors: Connie M. Ulrich, Christine Grady
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 19740: BMP9 Induces Non-Canonical Activation of the Microvascular Endothelium in Pulmonary Arterial Hypertension
Authors: Robert Szulcek, Nina Rol, Xiaoke Pan, Chris Dickhoff, Wim Timens, Marie-José Goumans, Harm-Jan Bogaard
Journal: Circulation (2017)

Introduction: Pulmonary Arterial Hypertension (PAH) comprises a group of deadly lung diseases in which disbalanced transforming growth factor beta (TGFβ) and bone morphogenetic protein (BMP) signal...
Characteristics of nonsteroidal anti-inflammatory drugs hypersensitivity at Songklanagarind Hospital
Authors: Wassamon Phattarapongdilok, Araya Yuenyongviwat, Wipa Jessadapakorn, Nisarat Chantaravisarut, Pasuree Sangsupawanich
Journal: Journal of Allergy and Clinical Immunology (2019)
DDT and Breast Cancer: Prospective Study of Induction Time and Susceptibility Windows
Authors: Barbara A Cohn, Piera M Cirillo, Mary Beth Terry
Journal: JNCI Journal of the National Cancer Institute (2018)

Abstract Background In a previous Child Health and Development Studies report, p, p’-DDT was associated with a fivefold increased risk of premenopausal (before age 50 years) breast cancer for women first exposed before puberty. Here we extend our observation to breast cancer diagnosed during early postmenopause (ages 50–54 years) to determine whether age at diagnosis modifies the interaction of DDT with age at exposure. Methods We conducted a second prospective, nested case-control study in the Child Health and Development Studies (153 incident breast cancer cases diagnosed at ages 50–54 years and 432 controls matched to cases on birth year). These were analyzed separately and pooled with our previous study (129 breast cancer cases diagnosed at ages 31–49 years and 129 controls matched on birth year). Blood samples were obtained during pregnancy (median age, 26 years), 1–3 days after delivery from 1959 to 1967 in Oakland, California. Serum was assayed for p, p’-DDT, o, p’-DDT, and p, p’-DDE. Odds ratios (ORs) below are given for doubling of serum p, p’-DDT. All statistical tests were two-sided. Results For early postmenopausal breast cancer, p, p’-DDT was associated with risk for all women (ORDDT 50–54 = 1.99, 95% CI = 1.48 to 2.67). This association was accounted for by women first exposed to DDT after infancy (ORDDT 50–54 for first exposure after infancy = 2.83, 95% CI = 1.96 to 4.10 vs ORDDT 50–54 for first exposure during infancy = 0.56, 95% CI = 0.26 to 1.19; Pinteraction DDT x age at first exposure = .01). In contrast, for premenopausal breast cancer, p, p’-DDT was associated with risk among women first exposed during infancy through puberty, but not after (ORDDT&lt;50 for first exposure during infancy = 3.70, 95% CI = 1.22 to 11.26, Pinteraction DDT x age at first exposure x age at diagnosis = .03). Conclusions p, p’-DDT was associated with breast cancer through age 54 years. Risk depended on timing of first exposure and diagnosis age, suggesting susceptibility windows and an induction period beginning in early life. DDT appears to be an endocrine disruptor with responsive breast targets from in utero to menopause.
泛发重度 EBS 是一种炎症性疾病
Authors: E. Castela, M.K. Tulic, A. Rozières, E. Bourrat, J.‐F. Nicolas, J. Kanitakis, P. Vabres, D. Bessis, J. Mazereeuw, F. Morice‐Picard, D. Baty, F. Berard, J.‐P. Lacour, T. Passeron, C. Chiaverini
Journal: British Journal of Dermatology (2019)

大疱性表皮松解 (EB) 是一组遗传性疾病,在此类疾病中,皮肤异常脆弱。在单纯性 EB 中,皮肤细胞容易瓦解,因为它们的内部角蛋白纤维骨架因编码 5 或 14 型角蛋白的基因(KRT5 和 KRT14)突变而存在缺陷。但有时,泛发重度单纯性 EB (EBS‐GS) 患者的病情仅仅因为皮肤出现机械性问题就会比预期更严重;一些人甚至在婴儿期死亡,通常因感染所致。这个来自法国和苏格兰的小组调查了 EBS‐GS 患者也存在免疫系统缺陷的可能性。他们重新研究了之前出于诊断目的从 17 名 EBS‐GS 患者中获得的皮肤标本,还检测了来自另外 10 名患者的新鲜皮肤活检标本和疱液。他们始终发现炎症细胞数量和促炎化学物质(细胞因子)水平高于正常值。无论标本来自有水疱还是正常外观的皮肤,也无论缺陷是 KRT5 还是 KRT14,上述发现都是相同的。细胞因子 Th17 的标记物水平尤其高,这鼓励他们用抗‐Th17 药物“阿普斯特”来治疗三名 EBS‐GS 患者,用药方法与用于银屑病时相同。全部三名患者均在第 1 个月内报告水疱显著减少,并且这种效果在整个治疗过程中持续,最长持续 10 个月,副作用极其轻微。一名患者在 7 个月后因为恶心停用阿普斯特,水疱在两天后重现。这有望成为治疗 EBS‐GS 的一种新方法。
Endoscopic submucosal dissection using a novel endoscopic articulating knife for clinical staging of early esophageal neoplasia.
Authors: Juan Genere, Harshith Priyan, Kenneth Wang
Journal: Journal of Clinical Oncology (2019)

114 Background: Clinical staging of early esophageal neoplasia traditionally involves histological confirmation and imaging with endoscopic ultrasound (EUS), CT, and PET which have low sensitivity and specificity for staging esophageal cancer (EC). Endoscopic submucosal dissection (ESD) therapy is traditionally used for treatment, but not diagnosis as it is felt to be technically challenging and have a high risk for complications. We applied a new articulating endoscopic knife that permits safe ESD (ESD-CC) to evaluate early neoplasia with potential curative resection. Methods: We performed a retrospective study of patients undergoing ESD to stage or treat suspected early EC (cT1-T2). Clinical stage was done by EUS, CT, and PET. Two expert GI pathologists reviewed all histology. Lesions were examined with high resolution white light endoscopy and narrow band imaging. ESD was done with 1:200,000 epinephrine and methylene blue dye injection for lifting and staining the submucosal space. A 5mm, scissors-like articulated knife was used to perform ESD and hemostasis. Complications during post-ESD observation or follow-up were recorded. Results: A total of 35 patients who underwent ESD-CC were included with median age 70 (IQR 12), 26 males (74%), and followed for a median 3.4 months (IQR 6.4). This group consisted of 32 potential adenocarcinomas and 3 squamous cell cancers. The clinical Pre-ESD diagnoses were cT1 EC (24, 69%) and suspected EC in Barrett’s esophagus (BE) (11, 31%). The cT1 EC cases had ESD staged at least T1b (5, 21%), T1a (11, 46%), EC in situ (1, 4%), and dysplastic BE (7, 29%). The suspected EC cases had ESD staged at least T1b (1, 9%), T1a (2, 18%), and DBE (8, 73%). ESD-CC up-staged 4 (11%), down-staged 10 (29%), and confirmed prior diagnosis in 21 (60%). No complications including bleeding, perforation, or stricture formation regardless of size of ESD, age of patient, or co-morbidities. Conclusions: Staging of early esophageal cancer can be improved using ESD with an articulating knife, without increase in complications. ESD may be used as a staging modality in early esophageal cancer.
Impact of radiation dose during neoadjuvant chemoradiation on postoperative complications in esophageal (EC) and gastroesophageal junction cancers (GEJC).
Authors: Noah Kastelowitz, Megan D. Marsh, Martin McCarter, Robert A. Meguid, Tracey E. Schefter, Douglas A. Rooke, Priscilla Stumpf, Stephen Leong, Wells A. Messersmith, Christopher Hanyoung Lieu, Alexis Diane Leal, S. Lindsey Davis, William T. Purcell, John D. Mitchell, Michael J. Weyant, Christopher Scott, Karyn A. Goodman
Journal: Journal of Clinical Oncology (2019)

119 Background: Neoadjuvant chemoradiation (nCRT) followed by resection is standard of care for operable stage II-III EC and GEJC; however, it can be associated with significant risk of postoperative complications (POC). The CROSS study group reported no increase in POC severity with nCRT using 41.4 Gy compared to surgery alone as defined by the Comprehensive Complication Index (CCI). We applied the CCI metric to evaluate the impact of nCRT radiation dose of &lt; 50 Gy vs. ≥ 50 Gy on POC rates and compared to the CROSS rates. Methods: We retrospectively reviewed 82 pts (2004-2016) with EC or GEJC treated with nCRT followed by resection at our institution. 29 (35%) pts were treated with &lt; 50 Gy (range 39.6-46.8 Gy) and 53 (65%) were treated with ≥ 50 Gy (range 50.0-52.5 Gy) delivered using IMRT/VMAT (41%), 3D-CRT (46%), or tomotherapy IMRT (12%). Concurrent chemotherapy were carboplatin/paclitaxel (59%), cisplatin/5-FU (17%), or other (24%). Resection was performed by Ivor Lewis esophagectomy (67%), esophagogastrectomy (14%), or trans-hiatal approach (11%). POC within 30 days were graded using the Clavien-Dindo scale and CCI scores were computed and compared between the two dose groups and with the CROSS nCRT group. Results: CCI scores and complication rates between our &lt; 50 Gy and ≥ 50 Gy groups were not significantly different. Assuming a normal distribution of the CROSS CCI scores, there was no significant difference in CCI scores between the CROSS study nCRT, &lt; 50 Gy, or ≥ 50 Gy groups. Rates of pulmonary complications were greater in the CROSS study. Conclusions: In highly selected EC and GEJC pts, definitive nCRT radiation doses do not appear to increase POC rates. Thus, 50 Gy can likely be delivered without increasing toxicity while also achieving a definitive dose for pts not able or willing to undergo subsequent surgery. [Table: see text]
Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer.
Authors: Ronan Joseph Kelly, Kellie Nicole Smith, Valsamo Anagnostou, Elizabeth Thompson, Russell K. Hales, Richard J. James Battafarano, K Ranh Voong, Stephen C. Yang, Josephine Louella Feliciano, Eun Ji Shin, Chen Hu, Margueritta El Asmar, Hok Yee Chan, Victor E. Velculescu, Cynthia Sears, Drew M. Pardoll, Ali Imran Amjad, Patrizia Guerrieri, Blair Anderson Jobe, Ali Hussainy Zaidi
Journal: Journal of Clinical Oncology (2019)

142 Background: Neoadjuvant chemoradiation (cRT) prior to surgical resection in stage II/III esophageal/gastroesophageal junction (E/GEJ) cancer results in a complete pathologic response rate (pCR) of 20-30%. The appearance of favorable microenvironment features (enhanced tumor infiltrating lymphocytes, perivascular lymphocytes and tertiary lymphoid structures) after induction therapy in resected EC suggest early stage tumors may respond favorably to immune based therapy and in particular to PD-1 blockade when combined with cRT. Methods: In this pilot study, we administered 2 cycles of induction nivolumab (N) q2 weekly prior to standard of care carboplatin/paclitaxel/radiation plus 3 additional cycles of N on week 1, 3 and 5 of cRT. An Ivor-Lewis esophagectomy (E/MIE) was performed 6-10 weeks after the last IO dose. The primary endpoints of the study were safety and feasibility. We also evaluated the pCR, survival and temporal dynamics of T cell receptor clonotypes. Results: Between August 2017 and July 2018, 16 patients were enrolled on study. Induction N and neoadjuvant N combined with cRT in stage II/III E/GEJ cancers has an acceptable toxicity profile and was not associated with delays in surgery. Toxicities of note include steroid responsive grade 3 dermatitis (1/16), grade 3 hepatitis (1/16) and no cases of pneumonitis. To date, 10 patients with E adenocarcinoma have had an E/MIE and the pCR is 4/10 (40%). T cell receptor sequencing of the tumor bed and serial peripheral blood T cells revealed high peripheral representation of tumor-associated T cells. In one notable case, the highest-frequency intratumoral clone decreased in frequency in the peripheral blood upon treatment and rapidly increased after surgical resection, potentially signifying trafficking to the tumor site. Conclusions: Induction N and N combined with cRT has limited side-effects, did not result in surgical delay or enhanced surgical morbidity/mortality and induced a pCR of 40% in stage II/III E/GEJ cancers. Additional efficacy data on the full cohort and more in depth correlative studies will be presented to validate systemic activation of anti-tumor T cell responses. Clinical trial information: NCT03044613.
Whole Genome Sequencing of Extramedullary Myeloma Autopsy Tumors Reveals a Genomic Portrait at Culmination of Clonal Convergence
Authors: Venkata D Yellapantula, Even H Rustad, Dominik Glozdik, Gunes Gundem, Jun Fan, Juan Medina, Akshar Patel, Minal Patel, Malin Hultcrantz, Jonathan U. Peled, Nikoletta Lendvai, Ola Landgren, Sergio Giralt, Christine Iacobuzio-Donahue, Elli Papaemmanuil, Heather J. Landau, Alexander M. Lesokhin
Journal: Blood (2018)